Lanthanum Carbonate Treatment of Patients with Hyperphosphatemia Undergoing CAPD

Kawanishi, Hiroaki; Ishida, Mari; Ishizaki, Makoto; Takuma, Yoshitaka; Tamura, Hirokazu; Kobayashi, Shuzo; Tamura, Tadao; Ohashi, Hiroshige; Hiramatsu, Masayuki; Murata, Jun; Hirakata, Hideki; Sügimura, Takashi

doi:10.1177/089686080802800622

Cited by 15 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mended to achieve a Kt/V of 1.7 as a minimum value, and ideal if a value Ն1.8 is achieved (199)(200)(201)(202)(203). Over time, an eventual decline in residual kidney function decreases the excretion of phosphorus in the urine.…”

Section: Jsdt Clinical Guideline On Ckd-mbd 265mentioning

confidence: 99%

“…The dialysis dose of a PD patient is evaluated by urea Kt/V per week (weekly Kt/V), with consideration given to the residual renal function. It is recommended to achieve a Kt/V of 1.7 as a minimum value, and ideal if a value ≥1.8 is achieved . Over time, an eventual decline in residual kidney function decreases the excretion of phosphorus in the urine.…”

Section: Rationalementioning

confidence: 99%

See 1 more Smart Citation

Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder

et al. 2013

View full text Add to dashboard Cite

Section: Jsdt Clinical Guideline On Ckd-mbd 265mentioning

confidence: 99%

Section: Rationalementioning

confidence: 99%

Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder

et al. 2013

View full text Add to dashboard Cite

“…Meanwhile, excessive Ca loading due to the use of Ca-based P binders may lead to vascular calcification and calciphylaxis, stressing the need for precautions against the development of hypercalcemia [13][14][15][16]. It is also important to exercise great caution when using drugs such as sevelamer hydrochloride [17,18], lanthanum carbonate [19,20], and cinacalcet hydrochloride [21], which are liable to Fig. 1 Percent achievement of the K/DOQI guideline for CKD-MBD, based on plasma concentrations at 3 months after the start of dialysis treatment [8].…”

Section: Dialysis Dose and Metabolism Of Ca And Pmentioning

confidence: 99%

Mineral bone disorders (MBD) in patients on peritoneal dialysis

2019

View full text Add to dashboard Cite

Chronic kidney disease-mineral bone disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism. In patients undergoing peritoneal dialysis (PD), serum levels of calcium (Ca), phosphate (P), and parathyroid hormone (PTH) remain relatively constant, irrespective of the timing of treatment. This is because PD is a continuous blood purification procedure, and in this respect differs greatly from hemodialysis (HD), where the serum levels of these factors change following each dialysis session, and so pre-dialysis values are considered baseline values. Nevertheless, the target values for serum P, Ca, and PTH in PD patients are the same as those in HD patients. In PD patients, however, it is plausible to initiate correction of any of these values once any tendency towards worsening is observed, even if they are still within the upper limit of normal for HD patients. Restriction of dietary P intake, conservation of residual renal function for excretion of P, and prescription of an appropriate P binder are recommended to maintain the blood P level in the appropriate range. The use of a 2.5-mEq/L Ca concentration dialysate reduces the risk of hypercalcemia and allows correction of adynamic bone disease. Meanwhile, secondary hyperparathyroidism may progress in such cases. It is thus recommended that this factor be considered in prescribing this type of dialysate.

show abstract

“…Unfortunately, less evidence and studies are available for patients undergoing PD [114]. An open, noncomparative study in patients with hyperphosphatemia undergoing continuous ambulatory PD evaluated safety and efficacy of lanthanum carbonate to reduce serum phosphate levels [120]. This study showed that lanthanum carbonate was generally well tolerated.…”

Section: Calcium-free Phosphate Bindersmentioning

confidence: 99%

The Bone and Mineral Disorder in Patients Undergoing Chronic Peritoneal Dialysis

Rroji¹,

Spahia²,

Barbullushi³

et al. 2018

Evolving Strategies in Peritoneal Dialysis

View full text Add to dashboard Cite

Disorders of mineral metabolism and bone disease are common complications in CKD patients. They are very complex and involve a number of feedback loops between the kidney, bone, intestine, and the vasculature associated with an increased morbidity and mortality and decreased quality of life of the patients. The work group of the kidney disease: Improving Global Outcomes (KDIGO) recommended in 2006 the use of the term chronic kidney disease-mineral and bone disorder (CKD-MBD) to describe a systemic disorder that incorporates these abnormalities. Compared to hemodialysis (HD), patients undergoing peritoneal dialysis (PD) appear to have an increased prevalence of low turnover bone disease defined as adynamic bone disease (ABD). The most important risk factors for ABD are age, oversuppression of parathyroid hormone (PTH) with vitamin D, diabetes, circulating antagonist PTH fragments, and frequent presence of a positive calcium balance, which may result in an oversuppression of PTH. PTH levels and bone phosphatase alkaline (bALP) should be assessed among such patients as the earliest markers of abnormal mineral and bone metabolism. Treatments considered are interventions to treat hyperphosphatemia, hyperparathyroidism, and bone disease. The optimal management of chronic kidney disease-mineral and bone disorder (CKD-MBD) includes the prevention of vascular calcifications.

show abstract

Lanthanum Carbonate Treatment of Patients with Hyperphosphatemia Undergoing CAPD

Cited by 15 publications

References 4 publications

Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder

Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder

Mineral bone disorders (MBD) in patients on peritoneal dialysis

The Bone and Mineral Disorder in Patients Undergoing Chronic Peritoneal Dialysis

Contact Info

Product

Resources

About